Controlled Release Drug Delivery Market Analysis

Report ID: 726
Published Date: Dec 23, 2024
Report Format: PDF, PPT

Buy Now

Controlled Release Drug Delivery Segmentation

The technology type in controlled release drug delivery market is segmented into wurster technique, implants, targeted delivery, micro encapsulation and others. Based on these segments, the targeted delivery segment will account for the leading share in the market on the back of its improved absorption, low risk of side effects, increased safety and it offers preferred site of action. Moreover, large number of key players has a strong portfolio for the technology. These factors, in turn, are expected to augment the market growth over the forecast period.

Our in-depth analysis of the global controlled release drug delivery market includes the following segments

By Product Type	Metered Dose Inhalers Injectables Nasal Sprays Infusion Pumps Drug Eluting Stents Others
By Technology Type	Wurster Technique Implants Micro Encapsulation Targeted Delivery Others
By Application Type	Oral Nasal Topical Implantable Injectable Targeted Delivery Others
By Release Mechanism	Polymer Based Systems Activation Modulated Osmotic Pressure Activated Mechanically Activated Vapour Pressure Activated Micro Reservoir Partition Chemically Activated Ph Activated Enzyme Activated
By End User	Hospitals Research Centres Government & Private Laboratories Personal Use Pharmaceutical Manufacturers Others

Browse key industry insights with market data tables & charts from the report:

Controlled Release Drug Delivery Market Size, Growth Trends 2037

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of controlled release drug delivery is estimated at USD 64.61 billion.

Controlled Release Drug Delivery Market size was valued at USD 59.83 billion in 2024 and is likely to cross USD 192.37 billion by 2037, expanding at more than 9.4% CAGR during the forecast period i.e., between 2025-2037.

North America industry is expected to account for largest revenue share by 2037, driven by prevailing diseases related to gastrointestinal disorders, advancement in the technological infrastructure of pharmaceutical industry, along with increasing activities of research & development.

The major players in the market are Pfizer Inc., Mayne Pharma, AstraZeneca Plc, Insulet Corporation, Becton Dickinson and Co, Bespak, West Pharmaceutical Services, Enable Injections Inc, Biogen Inc., and others.